REFERENCES

• KesslerRC.PetukhovaM.SampsonNA.ZaslavskyAM.WittchenHU.Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States.Int J Methods Psychiatr Res.201221316918422865617
   PubMed Web of Science ®Google Scholar
• WittchenHU.JacobiF.RehmJ.et alThe size and burden of mental disorders and other disorders of the brain in Europe 2010.Eur Neuropsychopharmacol.201121965567921896369
   PubMed Web of Science ®Google Scholar
• ChisholmD.SweenyK.SheehanP.et alScaling-up treatment of depression and anxiety: a global return on investment analysis.Lancet Psychiatry.20163541542427083119
   PubMed Web of Science ®Google Scholar
• JacobiF.HoflerM.StrehleJ.et alMental disorders in the general population: study on the health of adults in Germany and the additional module mental health (DEGS1-MH) [in German].Nervenarzt.2014851778724441882
   PubMed Web of Science ®Google Scholar
• KesslerRC.McGonagleKA.ZhaoS.et alLifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.Arch Gen Psychiatry.19945118198279933
   PubMed Web of Science ®Google Scholar
• KesslerRC.DemlerO.FrankRG.et alPrevalence and treatment of mental disorders, 1990 to 2003.N Engl J Med.2005352242515252315958807
   PubMed Web of Science ®Google Scholar
• BandelowB.MichaelisS.Epidemiology of anxiety disorders in the 21st century.Dialogues Clin Neurosci.201517332733526487813
   PubMed Web of Science ®Google Scholar
• KesslerRC.BerglundP.DemlerO.JinR.MerikangasKR.WaltersEE.Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.Arch Gen Psychiatry.200562659360215939837
   PubMed Web of Science ®Google Scholar
• AngstJ.GammaA.BaldwinDS.Ajdacic-GrossV.RosslerW.The generalized anxiety spectrum: prevalence, onset, course and outcome.Eur Arch Psychiatry Clin Neurosci.20092591374518575915
   PubMed Web of Science ®Google Scholar
• BandelowB.Epidemiology of depression and anxiety. In: Kasper S, den Boer JA, Ad Sitsen JM, eds.Handbook on Depression and Anxiety. New York, NY: M Dekker20034968
   Google Scholar
• RubioG.Lopez-IborJJ.Generalized anxiety disorder: a 40-year follow-up study.Acta Psychiatr Scand.2007115537237917430415
   PubMed Web of Science ®Google Scholar
• RubioG.Lopez-IborJJ Jr.What can be learnt from the natural history of anxiety disorders?Eur Psychiatry.2007222808617184975
   PubMed Web of Science ®Google Scholar
• BandelowB.BaldwinD.AbelliM.et alBiological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: neuroimaging and genetics.World J Biol Psychiatry.201617532136527403679
   PubMed Web of Science ®Google Scholar
• BandelowB.BaldwinD.AbelliM.et alBiological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: neurochemistry, neurophysiology and neurocognition.World J Biol Psychiatry.201718316221427419272
   PubMed Web of Science ®Google Scholar
• WittchenHU.KesslerRC.BeesdoK.KrauseP.HoflerM.HoyerJ.Generalized anxiety and depression in primary care: prevalence, recognition, and management.J Clin Psychiatry.200263(suppl 8)2434
   PubMed Web of Science ®Google Scholar
• MollerHJ.BandelowB.BauerM.et alDSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 1: general aspects and paradigmatic discussion of depressive disorders.Eur Arch Psychiatry Clin Neurosci.2015265151825119146
   PubMed Web of Science ®Google Scholar
• BandelowB.Comparison of the DSM-5 and ICD-10: panic and other anxiety disorders.CNS Spectr.201713
   Web of Science ®Google Scholar
• BaldwinDS.GordonR.AbelliM.PiniS.The separation of adult separation anxiety disorder.CNS Spectr.201621428929427503572
   PubMed Web of Science ®Google Scholar
• World Health Organization. ICD-11 Beta Draft. World Health Organization; 2017. http://apps.who.int/classifications/icd11/browse/f/en. Accessed February 17, 2017
   Google Scholar
• MollerHJ.BandelowB.VolzHP.BarnikolUB.SeifritzE.KasperS.The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice.Eur Arch Psychiatry Clin Neurosci.2016266872573627002521
   PubMed Web of Science ®Google Scholar
• KesslerRC.ChiuWT.DemlerO.MerikangasKR.WaltersEE.Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.Arch Gen Psychiatry.200562661762715939839
   PubMed Web of Science ®Google Scholar
• AlonsoJ.AngermeyerMC.BernertS.et al12-Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project.Acta Psychiatr Scand Suppl.2004 420283715128385
   PubMedGoogle Scholar
• HamiltonM.The assessment of anxiety states by rating.Br J Med Psychol.1959321505513638508
   PubMed Web of Science ®Google Scholar
• BandelowB.BroocksA.PekrunG.et alThe use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial.Pharmacopsychiatry.200033517418111071019
   PubMed Web of Science ®Google Scholar
• LiebowitzMR.Social phobia.Mod Probl Pharmacopsychiatry.1987221411732885745
   PubMedGoogle Scholar
• BandelowB.SherL.BuneviciusR.et alGuidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.int J Psychiatry Clin Pract.2012162778422540422
   PubMed Web of Science ®Google Scholar
• BandelowB.LichteT.RudolfS.WiltinkJ.BeutelME.The German guidelines for the treatment of anxiety disorders.Eur Arch Psychiatry Clin Neurosci.2015265536337325404200
   PubMed Web of Science ®Google Scholar
• BaldwinDS.AndersonIM.NuttDJ.et alEvidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.J Psychopharmacol.201428540343924713617
   PubMed Web of Science ®Google Scholar
• RegierDA.NarrowWE.RaeDS.ManderscheidRW.LockeBZ.GoodwinFK.The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services.Arch Gen Psychiatry.199350285948427558
   PubMed Web of Science ®Google Scholar
• AlonsoJ.LepineJP.ESEMeD/MHEDEA 2000 Scientific Committee. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD).J Clin Psychiatry.200768suppl 239
   PubMed Web of Science ®Google Scholar
• SmoldersM.LaurantM.VerhaakP.et alAdherence to evidence-based guidelines for depression and anxiety disorders is associated with recording of the diagnosis.Gen Hosp Psychiatry.200931546046919703640
   PubMed Web of Science ®Google Scholar
• BenjaminJ.Ben-ZionIZ.KarbofskyE.DannonP.Double-blind placebo-controlled pilot study of paroxetine for specific phobia.Psychopharmacology (Berl).2000149219419610805616
   PubMed Web of Science ®Google Scholar
• BandelowB.ZoharJ.HollanderE.et alWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders -first revision.World J Biol Psychiatry.20089424831218949648
   PubMed Web of Science ®Google Scholar
• CiprianiA.FurukawaTA.SalantiG.et alComparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.Lancet.2009373966574675819185342
   PubMed Web of Science ®Google Scholar
• MuscatelloMR.SpinaE.BandelowB.BaldwinDS.Clinically relevant drug interactions in anxiety disorders.Hum Psychopharmacol.201227323925322311403
   PubMed Web of Science ®Google Scholar
• StahlMM.LindquistM.PetterssonM.et alWithdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system.Eur J Clin Pharmacol.1997533-41631699476026
   PubMed Web of Science ®Google Scholar
• BaldwinDS.AjelK.MasdrakisVG.NowakM.RafiqR.Pregabalin for the treatment of generalized anxiety disorder: an update.Neuropsychiatr Dis Treat.2013988389223836974
   PubMed Web of Science ®Google Scholar
• ThanacoodyHK.ThomasSH.Tricyclic antidepressant poisoning: cardiovascular toxicity.Toxicol Rev.200524320521416390222
   PubMedGoogle Scholar
• StahlSM.Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder.J Clin Psychiatry.200263975675712363113
   PubMed Web of Science ®Google Scholar
• StarcevicV.The reappraisal of benzodiazepines in the treatment of anxiety and related disorders.Expert Rev Neurother.201414111275128625242262
   PubMed Web of Science ®Google Scholar
• SchweizerE.RickelsK.CaseWG.GreenblattDJ.Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper.Arch Gen Psychiatry.199047109089152222130
   PubMed Web of Science ®Google Scholar
• RickelsK.SchweizerE.CaseWG.GreenblattDJ.Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation [published erratum appears in Arch Gen Psychiatry 1991;48(1):51].Arch Gen Psychiatry.199047108999072222129
   PubMed Web of Science ®Google Scholar
• SmithDE.LandryMJ.Benzodiazepine dependency discontinuation: focus on the chemical dependency detoxification setting and benzodiazepine-polydrug abuse.J Psychiatr Res.199024suppl 21451561980693
   PubMedGoogle Scholar
• BradwejnJ.Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions.Can J Psychiatry.199338suppl 4S109S1137905780
   PubMedGoogle Scholar
• ShaderRI.GreenblattDJ.Use of benzodiazepines in anxiety disorders.N Engl J Med.1993328139814058292115
   PubMed Web of Science ®Google Scholar
• LivingstonMG.Benzodiazepine dependence.Br J Hosp Med.19945162812868032563
   PubMed Web of Science ®Google Scholar
• NelsonJ.ChouinardG.Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology.Can J Clin Pharmacol.199962698310519733
   PubMedGoogle Scholar
• SchweizerE.RickelsK.De MartinisN.CaseG.Garcia-EspanaF.The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients.Psychol Med.19982837137209626727
   PubMed Web of Science ®Google Scholar
• RickelsK.Benzodiazepines in the treatment of anxiety.Am J Psychother.19823633583706128929
   PubMed Web of Science ®Google Scholar
• BandelowB.LichteT.RudolfS.WiltinkJ.BeutelME.The diagnosis of and treatment recommendations for anxiety disorders.Dtsch Arztebl Int.201411127-2847348025138725
   PubMed Web of Science ®Google Scholar
• BerneyP.HalperinD.TangoR.Daeniker-DayerI.SchulzP.A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorders.Psychopharmacol Bull.2008413394718779775
   PubMedGoogle Scholar
• GoddardAW.BrouetteT.AlmaiA.JettyP.WoodsSW.CharneyD.Early coadministration of clonazepam with sertraline for panic disorder.Arch Gen Psychiatry.200158768168611448376
   PubMed Web of Science ®Google Scholar
• OttoMW.PollackMH.SachsGS.ReiterSR.Meltzer-BrodyS.RosenbaumJF.Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder.Am J Psychiatry.199315010148514908379551
   PubMed Web of Science ®Google Scholar
• SpiegelDA.Psychological strategies for discontinuing benzodiazepine treatment.J Clin Psychopharmacol.1999196 suppl 217S22S10587280
   PubMed Web of Science ®Google Scholar
• SteinDJ.AhokasAA.de BodinatC.Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.J Clin Psychopharmacol.200828556156618794654
   PubMed Web of Science ®Google Scholar
• SteinDJ.AhokasA.AlbarranC.OlivierV.AllgulanderC.Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.J Clin Psychiatry.20127371002100822901350
   PubMed Web of Science ®Google Scholar
• SteinDJ.AhokasA.MarquezMS.et alAgomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.J Clin Psychiatry.201475436236824569045
   PubMed Web of Science ®Google Scholar
• SteinDJ.AhokasA.JaremaM.et alEfficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.Eur Neuropsychopharmacol.20172752653728298261
   PubMed Web of Science ®Google Scholar
• MontgomerySA.KennedySH.BurrowsGD.LejoyeuxM.HindmarchI.Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, doubleblind, placebo-controlled discontinuation study.Int Clin Psychopharmacol.200419527128015289700
   PubMed Web of Science ®Google Scholar
• GoodwinGM.EmsleyR.RembryS.RouillonF.Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.J Clin Psychiatry.20097081128113719689920
   PubMed Web of Science ®Google Scholar
• SerrettiA.ChiesaA.Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.J Clin Psychopharmacol.200929325926619440080
   PubMed Web of Science ®Google Scholar
• McAllister-WilliamsRH.BaldwinDS.HaddadPM.BazireS.The use of antidepressants in clinical practice: focus on agomelatine.Hum Psychopharmacol.20102529510220196187
   PubMed Web of Science ®Google Scholar
• BandelowB.ChouinardG.BobesJ.et alExtended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placeboand active-controlled study.Int J Neuropsychopharmacol.201013330532019691907
   PubMed Web of Science ®Google Scholar
• KhanA.JoyceM.AtkinsonS.EggensI.BaldytchevaI.ErikssonH.A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.J Clin Psychopharmacol.201131441842821694613
   PubMed Web of Science ®Google Scholar
• FuJ.PengL.LiX.The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis.Neuropsychiatr Dis Treat.20161295195927143896
   PubMed Web of Science ®Google Scholar
• KasperS.GastparM.MullerWE.et alLavender oil preparation Silexan is effective in generalized anxiety disorder -a randomized, double+-blind comparison to placebo and paroxetine.Int J Neuropsychopharmacol.201417685986924456909
   PubMed Web of Science ®Google Scholar
• KasperS.AnghelescuI.DienelA.Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep - a randomized, placebo-controlled trial.Eur Neuropsychopharmacol.201525111960196726293583
   PubMed Web of Science ®Google Scholar
• KasperS.VolzHP.DienelA.SchlafkeS.Efficacy of Silexan in mixed anxiety-depression -a randomized, placebo-controlled trial.Eur Neuropsychopharmacol.201626233134026718792
   PubMed Web of Science ®Google Scholar
• WoelkH.SchlafkeS.A multi-center, double-blind, randomised study of the lavender oil preparation Silexan in comparison to lorazepam for generalized anxiety disorder.Phytomedicine.2010172949919962288
   PubMed Web of Science ®Google Scholar
• JacobsBP.BentS.TiceJA.BlackwellT.CummingsSR.An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia.Medicine (Baltimore).200584419720716010204
   PubMed Web of Science ®Google Scholar
• ConnorKM.PayneV.DavidsonJR.Kava in generalized anxiety disorder: three placebo-controlled trials,int Clin Psychopharmacol.200621524925316877894
   PubMed Web of Science ®Google Scholar
• SarrisJ.StoughC.BousmanCA.et alKava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study.J Clin Psychopharmacol.201333564364823635869
   PubMed Web of Science ®Google Scholar
• AndreatiniR.SartoriVA.SeabraML.LeiteJR.Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebocontrolled pilot study.Phytother Res.200216765065412410546
   PubMed Web of Science ®Google Scholar
• KobakKA.TaylorLV.BystritskyA.et alSt John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study.Int Clin Psychopharmacol.200520629930416192837
   PubMed Web of Science ®Google Scholar
• SarrisJ.PanossianA.SchweitzerI.StoughC.ScholeyA.Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence.Eur Neuropsychopharmacol.2011211284186021601431
   PubMed Web of Science ®Google Scholar
• WurglicsM.WesterhoffK.KaunzingerA.et alComparison of German St. John's wort products according to hyperforin and total hypericin content.J Am Pharm Assoc (Wash).200141456056611486982
   PubMedGoogle Scholar
• BandelowB.ReittM.RoverC.MichaelisS.GorlichY.WedekindD.Efficacy of treatments for anxiety disorders: a meta-analysis.Int Clin Psychopharmacol.201530418319225932596
   PubMed Web of Science ®Google Scholar
• DurhamRC.ChambersJA.PowerKG.et alLong-term outcome of cognitive behaviour therapy clinical trials in central Scotland.Health Technol Assess.20059421174
   PubMed Web of Science ®Google Scholar
• StocchiF.NorderaG.JokinenRH.et alEfficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder.J Clin Psychiatry.200364325025812716265
   PubMed Web of Science ®Google Scholar
• MontgomerySA.NilR.Durr-PalN.LoftH.BoulengerJP.A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.J Clin Psychiatry.200566101270127816259540
   PubMed Web of Science ®Google Scholar
• SteinDJ.VersianiM.HairT.KumarR.Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study.Arch Gen Psychiatry.200259121111111812470127
   PubMed Web of Science ®Google Scholar
• DavidsonJR.WittchenHU.LlorcaPM.et alDuloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.Eur Neuropsychopharmacol.200818967368118559291
   PubMed Web of Science ®Google Scholar
• KatzmanMA.Brawman-MintzerO.ReyesEB.OlaussonB.LiuS.ErikssonH.Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.Int Clin Psychopharmacol.2011261112420881846
   PubMed Web of Science ®Google Scholar
• BaldwinDS.SteinDJ.DolbergOT.BandelowB.How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.Hum Psychopharmacol.200924426927519334042
   PubMed Web of Science ®Google Scholar
• YoshinagaN.MatsukiS.NiitsuT.et alCognitive behavioral therapy for patients with social anxiety disorder who remain symptomatic following antidepressant treatment: a randomized, assessor-blinded, controlled trial.Psychother Psychosom.201685420821727230862
   PubMed Web of Science ®Google Scholar
• SchuurmansJ.van BalkomA.Late-life anxiety disorders: a review.Curr Psychiatry Rep.201113426727321538031
   PubMed Web of Science ®Google Scholar
• HallJ.KellettS.BerriosR.BainsMK.ScottS.Efficacy of cognitive behavioral therapy for generalized anxiety disorder in older adults: systematic review, meta-analysis, and meta-regression.Am J Geriatr Psychiatry.201624111063107327687212
   PubMed Web of Science ®Google Scholar
• HussainFS.DobsonET.StrawnJR.Pharmacologic treatment of pediatric anxiety disorders.Curr Treat Options Psychiatry.20163215116027648401
   PubMedGoogle Scholar
• IpserJC.SteinDJ.HawkridgeS.HoppeL.Pharmacotherapy for anxiety disorders in children and adolescents.Cochrane Database Syst Rev.2009 3CD00517019588367
   PubMed Web of Science ®Google Scholar
• WalkupJT.AlbanoAM.PiacentiniJ.et alCognitive behavioral therapy, sertraline, or a combination in childhood anxiety.N Engl J Med.2008359262753276618974308
   PubMed Web of Science ®Google Scholar
• Committee on Safety of Medicines (2014). Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs): use and safety. Medicines & Healthcare products Regulatory Agency (MHRA). Available at: https://www.gov.uk/government/publications/ssris-and-snris-use-and-safety/selective-serotonin-reuptake-inhibitors-ssris-and-serotonin-and-noradrenaline-reuptake-inhibitors-snris-useand-safety. Accessed 18 May 2017.
   Google Scholar
• HetrickSE.McKenzieJE.CoxGR.SimmonsMB.MerrySN.Newer generation antidepressants for depressive disorders in children and adolescents.Cochrane Database Syst Rev.201211CD00485123152227
   PubMedGoogle Scholar
• LibbyAM.BrentDA.MorratoEH.OrtonHD.AllenR.ValuckRJ.Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.Am J Psychiatry.2007164688489117541047
   PubMed Web of Science ®Google Scholar
• GibbonsRD.BrownCH.HurK.et alEarly evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents.Am J Psychiatry.200716491356136317728420
   PubMed Web of Science ®Google Scholar
• MohattJ.BennettSM.WalkupJT.Treatment of separation, generalized, and social anxiety disorders in youths.Am J Psychiatry2014171774174824874020
   PubMed Web of Science ®Google Scholar
• BergmanRL.GonzalezA.PiacentiniJ.KellerML.Integrated Behavior Therapy for Selective Mutism: a randomized controlled pilot study.Behav Res Ther.2013511068068923933108
   PubMed Web of Science ®Google Scholar
• OerbeckB.SteinMB.Wentzel-LarsenT.LangsrudO.KristensenH.A randomized controlled trial of a home and school-based intervention for selective mutism - defocused communication and behavioural techniques.Child Adolesc Ment Health.2014193192198
   PubMed Web of Science ®Google Scholar
• ManassisK.OerbeckB.OvergaardKR.The use of medication in selective mutism: a systematic review.Eur Child Adolesc Psychiatry.201625657157826560144
   PubMed Web of Science ®Google Scholar
• HuybrechtsKF.PalmstenK.AvornJ.et alAntidepressant use in pregnancy and the risk of cardiac defects.N Engl J Med.2014370252397240724941178
   PubMed Web of Science ®Google Scholar
• OyebodeF.RastogiA.BerrisfordG.CocciaF.Psychotropics in pregnancy: safety and other considerations.Pharmacol Ther.20121351717722483705
   PubMed Web of Science ®Google Scholar
• MuzikM.HamiltonSE.Use of antidepressants during pregnancy?: What to consider when weighing treatment with antidepressants against untreated depression.Matern Child Health J.201620112268227927461022
   PubMed Web of Science ®Google Scholar
• GilroyLJ.KirkbyKC.DanielsBA.MenziesRG.MontgomeryIM.Controlled comparison of computer-aided vicarious exposure versus live exposure in the treatment of spider phobia.Behavior Therapy.2001314733744
   Web of Science ®Google Scholar
• PattersonB.BoyleMH.KivlenieksM.Van AmerlngenM.The use of waitlists as control conditions in anxiety disorders research.J Psychiatr Res.20168311212027585425
   PubMed Web of Science ®Google Scholar
• JamesAC.JamesG.CowdreyFA.SolerA.ChokeA.Cognitive behavioural therapy for anxiety disorders in children and adolescents.Cochrane Database Syst Rev.2015 2CD00469025692403
   PubMed Web of Science ®Google Scholar
• BroocksA.BandelowB.PekrunG.et alComparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder.Am J Psychiatry.199815556036099585709
   PubMed Web of Science ®Google Scholar
• WedekindD.BroocksA.WeissN.EngelK.NeubertK.BandelowB.A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder.World J Biol Psychiatry.201011790491320602575
   PubMed Web of Science ®Google Scholar
• World Health Organization.ICD-10 Chapter V (F) Classification of Mental and Behvioural Disorders: Clinical Descriptions and Diagnostic Guidelines. “Blue Book” Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization;1991
   Google Scholar